Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Equity Raises:
- On June 30, 2025, Cel Ai PLC (CLAI: LSE), a British company engaged in the provision of consumer products based on biosynthetic cannabinoids, whose products include skincare and topical athletic recovery products, completed a private placement of common shares for gross proceeds of $13.7M.
- Five billion shares were sold for $0.0027 per share.
- The proceeds of the issue will be used to acquire BTC and fund ongoing operations. The company’s Chairperson remarked that “This funding provides us with the resources to continue growing our core business and delivering on the opportunities ahead. At the same time, introducing a bitcoin treasury approach will enable us to take a forward-thinking stance on capital management.”
- Apparently, one man’s investment is another man’s speculation. The company increased its market cap by more than 7.5 times with this issue, which is, in itself, an unusually bold move. However, investing it in Bitcoin seems bizarre to us. After all, if prospective shareholders wanted to invest in bitcoin, rather than a cannabinoid product company, wouldn’t it be simpler to do so directly?
Public vs. Private Raises:
- The only capital raiser of the week was a public company that trades on the London Stock Exchange.
Equity vs. Debt Cap Raises:
- Debt accounted for 93% of trailing 8-week capital raises. The ratio may go down if companies are able to utilize favorable regulatory-induced stock price increases to complete equity issues. However, equity pricing has remained stubbornly low while the cannabis debt capital markets have reopened.
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.